Le Lézard
Classified in: Health
Subjects: NPT, SVY, TRI, PET

Reversing a genetic cause of poor stress responses in mice


COLD SPRING HARBOR, N.Y., April 7, 2021 /PRNewswire/ -- Everyone faces stress occasionally, whether in school, at work, or during a global pandemic. However, some cannot cope as well as others. In a few cases, the cause is genetic. In humans, mutations in the OPHN1 gene cause a rare X-linked disease that includes poor stress tolerance. Cold Spring Harbor Laboratory (CSHL) Professor Linda Van Aelst seeks to understand factors that cause specific individuals to respond poorly to stress. She and her lab studied the mouse gene Ophn1, an analog of the human gene, which plays a critical role in developing brain cell connections, memories, and stress tolerance. When Ophn1 was removed in a specific part of the brain, mice expressed depression-like helpless behaviors. The researchers found three ways to reverse this effect. 

To test for stress, the researchers put mice into a two-room cage with a door in between. Normal mice escape from the room that gives them a light shock on their feet. But animals lacking Ophn1 sit helplessly in that room without trying to leave. Van Aelst wanted to figure out why.

Her lab developed a way to delete the Ophn1 gene in different brain regions. They found that removing Ophn1 from the prelimbic region of the medial prefrontal cortex (mPFC), an area known to influence behavioral responses and emotion, induced the helpless phenotype. Then the team figured out which brain circuit was disrupted by deleting Ophn1, creating overactivity in the brain region and ultimately the helpless phenotype.

Understanding the circuit
Pyramidal neurons are central to this brain circuit. If they fire too much, the mouse becomes helpless.

Another cell, an interneuron, regulates the pyramidal neuron activity, making sure it does not fire too much.

These two cells feedback to each other, creating a loop.

Ophn1 controls a particular protein, RhoA kinase, within this feedback loop which helps regulate and balances activity.

Van Aelst found three agents that reversed the helpless phenotype. Fasudil, an inhibitor specific for RhoA kinase, mimicked the effect of the missing Ophn1. A second drug dampens excess pyramidal neuron activity. A third drug wakes up the interneurons to inhibit pyramidal neurons. Van Aelst says:

"So bottom line, if you can restore the proper activity in the medial prefrontal cortex, then you could rescue the phenotype. So that was actually very exciting. You should be open to anything. You never know. Everything is surprising."

Van Aelst hopes that understanding the complex feedback loop behind Ophn1-related stress responses will lead to better treatments for stress in humans.

About Cold Spring Harbor Laboratory
Founded in 1890, Cold Spring Harbor Laboratory has shaped contemporary biomedical research and education with programs in cancer, neuroscience, plant biology and quantitative biology. Home to eight Nobel Prize winners, the private, not-for-profit Laboratory employs 1,100 people including 600 scientists, students and technicians. For more information, visit www.cshl.edu

SOURCE Cold Spring Harbor Laboratory


These press releases may also interest you

at 02:54
HanxBio today announced that it has published a research article titled "Narazaciclib, a novel multikinase inhibitor with potent activity against CSF1R, FLT3 and CDK6, shows strong anti-AML activity in defined preclinical models" in the Nature...

at 02:50
International medical imaging IT and cybersecurity company Sectra (STO: SECT B) has signed two contracts to provide the radiology module of its enterprise imaging solution with two university medical centers in Germany?Universitätsklinikum Tübingen...

at 02:24
Today, 23 April 2024, the subscription period in SciBase Holding AB (publ) ('SciBase' or the 'Company') rights issue of units of up to approximately SEK 15 million commences (the 'Rights Issue'). The Rights Issue was resolved by the Board of...

at 02:05
Antech, the veterinary diagnostics company focused on partnering with veterinary professionals to predict, diagnose, and monitor wellness and disease, today announced the launch of the breakthrough in-hospital Nu.Q® Canine Cancer Test in Europe. A...

at 02:00
Red Arrow Therapeutics Inc. closed a $4.5M Seed Extension round, raising from four, top-tier institutional investors in Japan. Participants of this round are: Beyond Next Ventures Inc.The University of Tokyo Edge Capital Partners Co., Ltd.Keio...

at 01:05
Investment funds managed by KKR, a leading global investment firm, have agreed to acquire Immedica Pharma, a pharmaceutical company headquartered in Stockholm, Sweden, focused on the commercialization of medicines for rare diseases and specialty care...



News published on and distributed by: